(Press-News.org) JANUARY 18, 2024, NEW YORK – A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.
Led by Ludwig Lausanne’s Leire Bejarano and Johanna Joyce, researchers also developed a platform to identify potentially targetable vulnerabilities in the vasculature of brain metastases. They report in the current issue of Cancer Cell their identification of one such target—a protein known as CD276—and show that its inhibition by antibodies markedly extends the survival of mice engineered to develop brain metastases of breast cancer.
“These findings represent a significant advance in our understanding of the complex interactions of blood vessels, immune cells and cancer cells within the brain and hold promise for the development of therapies that can target brain tumors in new and more effective ways,” said Joyce. “There’s a dire need for such therapies as most patients with brain metastases of these cancers survive less than one year after diagnosis.”
Like all solid tumors, brain metastases rely on a diverse crew of noncancerous cells that they often manipulate to survive and thrive. This includes not only immune cells—like macrophages and neutrophils—but also fibroblasts and, crucially, the cellular components of new blood vessels, without which tumors cannot grow at all.
The Joyce lab has extensively analyzed the immune landscapes of primary and metastatic brain tumors, identifying their constituent cells, examining how those cells are biochemically manipulated and functionally altered in each tumor type and harnessing those discoveries to advance new strategies to address tumor recurrence and resistance to therapy.
But far less is known about the vasculature of brain tumors, where new blood vessels engendered by cancer cells establish a functionally distinct blood-tumor barrier that serves and protects them, much as the blood-brain barrier does for healthy brain tissue.
To fill that gap, Bejarano, Joyce and colleagues conducted a deep analysis of the molecular features and gene expression patterns of cells that form the blood-brain barrier in noncancerous brain tissue and metastatic brain tumor samples freshly isolated from patients with the three major cancers. They then focused on endothelial cells (ECs), which line the inner vascular surface, and mural cells—pericytes and smooth muscle cells—that swaddle and stabilize blood vessels.
Their analysis revealed significant differences between gene expression patterns in these cells and those of the same cells obtained from noncancerous brain tissue. The patterns suggested multiple aberrations in tumor vessels, including problems in the intercellular junctions and adhesiveness of ECs and mural cells—reflecting the well-known “leakiness” of tumor blood vessels—and their elevated interactions with certain subsets of immune cells. These findings, and others obtained using advanced imaging methods, were recapitulated in studies conducted in mouse models of brain metastasis.
“This agreement validated our analysis of the brain tumor vasculature and supported the subsequent use of our mouse models as platforms for the identification and preclinical evaluation of new therapeutic approaches,” said Bejarano.
Studies in mice confirmed that mural cells and ECs regulate the trafficking of immune cells into brain metastases. The researchers identified several changes in molecular signaling pathways in the two cell types that suppress anti-tumor immune responses or induce the suicide of T cells that target cancer cells. They then focused on an immunosuppressive molecule, CD276, which they had found to be especially abundant in ECs and mural cells of brain metastases. An emerging target for cancer immunotherapy, CD276 is known to inhibit T cell proliferation, support immune evasion by cancer cells and is widely associated with poor patient outcomes.
Joyce, Bejarano and colleagues show in this study that antibodies targeted to CD276 inhibited brain tumor growth in a mouse model of breast cancer, and notably extended survival compared to mice treated with an analogous but ineffectual control antibody. They also show that the treatment altered the vasculature at the molecular level and boosted the infiltration of killer T cells into tumors.
“Beyond identifying CD276 as a candidate therapeutic target for brain metastases,” said Bejarano, “we identified many other potential drug targets for such tumors and validated a model system in which they can be reliably tested before they are developed further.”
This study was supported by Ludwig Cancer Research, the Swiss National Science Foundation, University of Lausanne, Carigest Foundation, Breast Cancer Research Foundation, the Lundin Brain Tumor Center, the European Molecular Biology Organization and Human Frontier Science Program.
In addition to her post as a Member of the Ludwig Institute for Cancer Research, Lausanne Branch, Joyce is also a Professor at the University of Lausanne.
# # #
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 50 years. Ludwig combines basic science with the translation and clinical evaluation of its discoveries to accelerate the development of new cancer diagnostics, therapies and prevention strategies. Since 1971, Ludwig has invested nearly $3 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For additional information please contact communications@ludwigcancerresearch.org.
END
We tend to separate the brain and the muscle—the brain does the thinking; the muscle does the doing. The brain takes in complex information about the world and makes decisions, and the muscle merely executes. This has also shaped how we think about a single cell; some molecules within cells are seen as ‘thinkers’ that take in information about the chemical environment and decide what the cell needs to do for survival; separately, other molecules are seen as the ‘muscle,’ building structures needed for survival.
But a new study shows how the molecules that build structures, i.e, the muscle, can themselves do both the thinking and the doing. The ...
CHAPEL HILL, NC – University of North Carolina at Chapel Hill scientists created a new drug delivery system, called the Spatiotemporal On-Demand Patch (SOP), which can receive commands wirelessly from a smartphone or computer to schedule and trigger the release of drugs from individual microneedles. The patch’s thin, soft platform resembles a Band-Aid and was designed to enhance user comfort and convenience, since wearability is a crucial factor for chronically ill patients.
The research team, led by Juan Song, PhD, professor of pharmacology ...
AUSTIN, Texas –– Artificial intelligence has become the Swiss Army knife of the business world, a universal tool for increasing sales, optimizing efficiency, and interacting with customers. But new research from Texas McCombs explores another purpose for AI in business: to contribute to the social good.
It can do so by helping businesses better serve vulnerable consumers: anyone in the marketplace who experiences limited access to and control of resources.
“AI is widely recognized for its operational and ...
Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
The antimalarial molecule, TDI-8304, is one of a new class of experimental therapeutics that targets the proteasome, an essential, multiprotein complex in P. falciparum cells. Two years ago, the researchers showed in a preclinical study that TDI-8304 potently kills malaria parasites at multiple stages of their life cycle and ...
RICHMOND, Va. (Jan. 18, 2024) – New research from Virginia Commonwealth University fundamentally challenges the paradigm that business organizations should promote profit above all else.
Christopher S. Reina, Ph.D., executive director of the VCU Institute for Transformative Leadership, lays out the foundation for transforming business to be much more people-centered and humanistic in “Humanistic Organizing: The Transformative Force of Mindful Organizational Communication.” ...
The quantum ground state of an acoustic wave of a certain frequency can be reached by completely cooling the system. In this way, the number of quantum particles, the so-called acoustic phonons, which cause disturbance to quantum measurements, can be reduced to almost zero and the gap between classical and quantum mechanics bridged.
Over the past decade, major technological advances have been made, making it possible to put a wide variety of systems into this state. Mechanical vibrations oscillating between ...
DALLAS, January 17, 2024 — The American Heart Association and National Football League are asking classrooms, afterschool programs and other student groups to join the NFL PLAY 60 Fitness Tracking Competition from Jan. 22 to Feb. 9. The classroom with the most activity minutes in each of the 32 NFL club markets will receive a $1,000 grant with an additional $1,000 PLAY 60 grant awarded to the top classroom overall. The competition and the goal of NFL PLAY 60 is to increase physical activity in kids which impacts overall mental and physical wellness which is essential to help children reach their full potential.
The NFL PLAY 60 Fitness Tracking Competition takes place ...
Electrical deep brain stimulation (DBS) is a well-established method for treating disordered movement in Parkinson’s disease. However, implanting electrodes in a person’s brain is an invasive and imprecise way to stimulate nerve cells. Researchers report in ACS’ Nano Letters a new application for the technique, called magnetogenetics, that uses very small magnets to wirelessly trigger specific, gene-edited nerve cells in the brain. The treatment effectively relieved motor symptoms in mice without damaging surrounding ...
Evolutionary biologists have long suspected that the diversification of a single species into multiple descendent species – that is, an “adaptive radiation” – is the result of each species adapting to a different environment. Yet formal tests of this hypothesis have been elusive owing to the difficulty of firmly establishing the relationship between species traits and evolutionary “fitness” for a group of related species that recently diverged from a common ancestral species.
A global team of biologists led by McGill University have compiled nearly two decades of field data – representing the study ...
(MEMPHIS, Tenn., January 18, 2024) St. Jude Children’s Research Hospital today announced a nearly $13 million investment toward a new research collaboration with scientists at Columbia University, Duke University and Stanford University to expand the understanding of G-protein coupled receptors (GPCR), which are vital proteins that impact human health and disease.
The collaborative research project is led by two St. Jude researchers, Scott Blanchard, Ph.D., and M. Madan Babu, Ph.D., who are working with Nobel laureate and Howard Hughes Medical Institute investigator Robert Lefkowitz, M.D., of Duke University; Jonathan Javitch, M.D., Ph.D., of ...
